GET THE APP

Comparing the diagnostic accuracy of PI-RADS Version 1

Journal of Clinical & Experimental Oncology.ISSN: 2324-9110

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Comparing the diagnostic accuracy of PI-RADS Version 1 and PI-RADS Version 2 using a radiologicpathologic correlation


Sara Fardin, Michael Nguyentat, Shane Knipping, Alexander Ushinsky, Layla Shirkhoda, Alessandra Miranda Aguirre, Christopher Green, Edward Uchio, Chandana Lall and Roozbeh Houshyar

University of California, Irvine, USA
: J Clin Exp Oncol

Abstract


Introduction: Multiparametric MRI (mpMRI) has been developed as an adjuvant tool for prostate cancer screening. MpMRI according to PI-RADSv1 criteria improved detection of prostate cancer, but studies evaluating PI-RADSv2 are lacking. Utilizing radiologic pathologic correlation through a combination of TRUS guided 12-core and MRI/TRUS fusion biopsies; we compared the diagnostic accuracy of mpMRI according to PI-RADSv1 versus PI-RADSv2. Methods: We retrospectively reviewed charts of patients with mpMRI utilizing PI-RADSv1 and subsequent combination biopsy (TRUS-guided 12-core biopsy plus MRI/TRUS fusion biopsy). The mpMRI studies were then re-graded to PI-RADSv2, by a radiologist blinded to biopsy results. An mpMRI with PI-RADS score of 3-5 was considered positive. Clinically significant cancer was defined as Gleason Score ≥7 or 6 with ≥50% tumor on core. Chi-square and ROC analyses were performed. Results: Our analysis included 76 men with a total of 124 identified prostate lesions on mpMRI. For clinically significant cancer, PIRADSv1 had a NPV, PPV, sensitivity, and specificity of 100%, 33.0%, 100%, and 20.2%, respectively. PI-RADSv2 had values of 100%, 41.2%, 100%, and 43.8%, respectively. Chi-square analysis showed a significant association between clinically significant cancer and both PI-RADSv1 score (p=0.004) and PIRADSv2 score (p<0.001). On ROC analysis, the AUC was 0.819 and 0.856 for PI-RADSv1 and PI-RADSv2, respectively. Discussion: MpMRI utilizing PI-RADSv2 criteria achieves a higher specificity and PPV. While both PI-RADS scores show statistically significant correlation with clinically significant cancer, the correlation was stronger using PI-RADSv2. Furthermore, there was an AUC increase of 0.037 when using PI-RADSv2 criteria. Compared to PI-RADSv1, PI-RADSv2 appears to have superior diagnostic accuracy for detecting clinically significant prostate cancer.

Biography


Sara Fardin has completed her Medical School in Tehran University of Medical Sciences and Radiology-Molecular Imaging Research Fellowship in the University of Pennsylvania. She is currently working as a Research Fellow in University of California, Irvine.

Email: sfardin@uci.edu

Track Your Manuscript

Media Partners